-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination ...
Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane ...
New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...
Drug combination screening is transforming treatment development by focusing on how multiple drugs can work together—rather than relying on a single therapy. This approach allows researchers to ...
Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates. In this episode, experts examine combination ...
Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE ...
Pelabresib plus Jakafi significantly reduced spleen volume and improved symptoms in myelofibrosis patients compared to Jakafi alone, with sustained benefits at 96 weeks. The combination therapy showed ...
Adaptive drug resistance represents one of the most critical barriers to durable responses in cancer therapy. Unlike static genetic resistance, adaptive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results